Karuna Therapeutics, Inc. (KRTX) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
William Meury	President, Chief Executive Officer & Director	0	1968
Stephen K. Brannan	Chief Medical Officer	751,750	1956
Andrew Craig Miller	Founder and President of Research & Development	835,400	1982
Frank Truslow	Senior Vice President of Corporate Development	0	N/A
Jason Parker Brown	Chief Financial Officer	0	1988
Jonathan Rosin	Chief Human Resources Officer	0	N/A
Alan Breier	Chair of Scientific Advisory Board & Chief Clinical Advisor	0	N/A
Mia Kelley	General Counsel	0	N/A
Ronald N. Marcus	Senior Vice President of Medical	0	1958
Alexis Smith	Vice President of Corporation Affairs & Investor Relations	0	N/A

Name

Title

Pay

Year Born

William Meury

President, Chief Executive Officer & Director

1968

Stephen K. Brannan

Chief Medical Officer

751,750

1956

Andrew Craig Miller

Founder and President of Research & Development

835,400

1982

Frank Truslow

Senior Vice President of Corporate Development

N/A

Jason Parker Brown

Chief Financial Officer

1988

Jonathan Rosin

Chief Human Resources Officer

N/A

Alan Breier

Chair of Scientific Advisory Board & Chief Clinical Advisor

N/A

Mia Kelley

General Counsel

N/A

Ronald N. Marcus

Senior Vice President of Medical

1958

Alexis Smith

Vice President of Corporation Affairs & Investor Relations

N/A

Description

Operating as a clinical-stage biopharmaceutical firm, Karuna Therapeutics, Inc. is dedicated to pioneering innovative therapies for individuals afflicted by psychiatric and neurological disorders. Its primary investigational compound, KarXT, is an oral agent designed to modulate muscarinic receptors. Currently in Phase III clinical trials, KarXT is being evaluated for several indications: the treatment of acute psychosis in schizophrenia patients, the amelioration of central nervous system conditions (including the negative and cognitive symptoms associated with schizophrenia and general psychosis), and the management of dementia-related psychosis. Beyond KarXT, the firm is also advancing a pipeline of other drug candidates that interact with muscarinic receptors. Karuna Therapeutics, Inc. has forged several strategic partnerships, encompassing licensing agreements with Eli Lilly and Company and Zai Lab (Shanghai) Co., Ltd., a patent license with PureTech Health LLC, and drug discovery collaborations with Charles River Laboratories and PsychoGenics, Inc. Established in 2009, the enterprise initially operated under the name Karuna Pharmaceuticals, Inc., before officially adopting its current corporate identity, Karuna Therapeutics, Inc., in March 2019. Its corporate headquarters are located in Boston, Massachusetts.